Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis

Abstract excerpt

Golimumab, a tumor necrosis factor antagonist, is an effective treatment for patients with moderate-to-severe ulcerative colitis (UC); however, more than 50% of initial responders lose their response to the drug within the first year of therapy. A gene expression signature identified in colon biopsies collected before treatment was associated with response to infliximab, and was subsequently refined to associate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Helicobacter pylori-related gastroenterology studies
• Share to Inflammatory Bowel Disease
• Share to Microscopic Colitis